Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure — Stella
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(3 sites) Germany
University Medical Center Göttingen, Göttingen, Lower Saxony Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, North Rhine-Westphalia University Medical Center Schleswig-Holstein, Lübeck, Schleswig-Holstein
Key details Phase
Early testing / Safety & dosing
Sponsor
University Medical Center Goettingen
Collaborators
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), University Medical Center Freiburg
Enrollment target
~53 participants
Primary completion
December 2027
Age range
18 Years – 80 Years
Last updated February 2026